

This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between these translated documents and the Japanese originals, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

**Disclosure on the Internet accompanying
the Notice of the 74th Annual General Meeting of Shareholders**

System to Ensure Proper Execution of Business and Status of Operation of the System	Page 1
Consolidated Statement of Changes in Shareholders' Equity	Page 6
Notes to Consolidated Financial Statements	Page 7
Statement of Changes in Shareholders' Equity	Page 24
Notes to Non-consolidated Financial Statements	Page 25

The aforementioned content is posted on the website of TOHO HOLDINGS ("the Company") (<https://ir.tohohd.co.jp/en/stock/meeting.html>) and is provided to the shareholders via the Internet, pursuant to laws and regulations and Article 14 of the Articles of Incorporation of the Company.

TOHO HOLDINGS CO., LTD.

System to Ensure Proper Execution of Business and Status of Operation of the System

The following descriptions outline the decisions made with respect to the system to ensure that the Directors' execution of duties complies with laws and regulations and the Articles of Incorporation, and other systems to ensure the proper execution of business of the Company.

Pursuant to the provisions of the Companies Act, the Company has established the following "Basic Policies for the Internal Control System," and will faithfully comply with the Basic Policies in order to ensure the legality and efficiency of the Company's business and to manage risks. In response to changes in social and economic conditions and other environments surrounding the Company, the Company will review the Basic Policies and seek to improve and enhance the Basic Policies.

(1) System to ensure that the Directors execute their duties in compliance with laws and regulations and the Articles of Incorporation

1) Under the "Kyoso Mirai Group Ethical Code" (hereinafter referred to as the "Ethical Code"), the Company has formulated the ethical standards and a code of conduct that must be followed in compliance with laws and regulations, as well as social norms. Directors and employees of the Kyoso Mirai Group act in accordance with this Ethical Code.

2) Pursuant to the provisions of laws and regulations, the Articles of Incorporation and the Board of Directors Rules, the Board of Directors makes decisions on the Company's execution of business and monitors and supervises the execution of business of group companies.

3) In order to ensure that the execution of duties of each Director will be supervised by the Board of Directors, each Director properly reports to the Board of Directors on the status of business execution by the Company and group companies and the Directors mutually monitor and supervise each other's execution of duties.

4) By executing duties in compliance with laws and regulations, the Articles of Incorporation, the Board of Directors Rules, Decision-Making (*Ringi*) Rules, etc., the Directors ensure proper decision-making and the execution of duties.

5) Pursuant to the provisions of the Financial Instruments and Exchange Act, the Directors establish and continuously operate and assess the system in which internal control over financial reporting of group companies is effectively and appropriately conducted, and ensure the reliability and appropriateness of the financial reporting of the Company group.

6) In order to ensure that the Company group's directors and employees execute their duties in compliance with laws, regulations, the Articles of Incorporation, and other rules, the Company shall introduce an internal reporting system, establish internal and external reporting contacts, and ensure that whistleblowers are not treated disadvantageously.

(2) System to ensure that the execution of duties by employees will be in compliance with laws and regulations and the Articles of Incorporation

1) In order to ensure that employees execute their duties while always being conscious of compliance, the Company strives so that the Ethical Code will be practically and fully applied under the control and supervision of the Group Management Committee. In particular, the Company makes efforts for maintaining and strengthening the system to ensure compliance with laws and regulations related to pharmaceutical affairs, laws and regulations for securing fair competition such as the Antimonopoly Act, strict control of corporate information and personal information, etc., and for providing employees with education and enlightening employees about the system.

2) The Company fully ensures that the business will be executed and managed through the office organization. If any problem arises, the Company will deal with them in a proper and strict manner in accordance with the rules of employment and immediately take measures to prevent any recurrence of such problem.

3) By periodically conducting internal audits, the Company checks whether the execution of duties by employees of the Company group complies with laws and regulations, the Articles of Incorporation, and various rules, and maintains and strengthens the proper execution of duties.

(3) System to preserve and control information concerning the Directors' execution of their duties

1) The Company properly preserves and controls the documents (including electronic records) related to the Directors' execution of their duties and other important information in accordance with laws and regulations and the "Document Handling Rules."

2) By undergoing audits conducted by the Audit and Supervisory Committee Members, the Company ensures the appropriateness of the creation, preservation, and control of information concerning the Directors' execution of duties.

(4) Rules and other systems related to the control of the risk of loss

1) Pursuant to the "Risk Management Basic Rules," the Company promotes the establishment of the Company group's risk management system, and makes efforts for early detection and understanding of any actual or potential risks that come to exist within the Company group, and for taking proper measures for such risks.

2) Through the Group Compliance Risk Management Committee, Group Disaster Countermeasure Committee, etc., the Company provides the Group Management Committee with risk information, and makes efforts for maintaining and improving the risk management system by taking appropriate measures.

3) If any unexpected circumstance occurs to the Company group, a task force will be established at the Company or a business operating company. The task force will be directed by the President (or a person appointed by the President) and take swift actions to organize a system to minimize damage and to maintain and establish the supply system for pharmaceuticals.

4) In order to maintain the normal operation of the computer processing systems, the Company introduced a back-up system by maintaining multiple data centers and has properly established a system in preparation for accidents.

(5) System to ensure that the Directors execute their duties in an efficient manner

1) As the basis for the system to ensure the Directors execute their duties in an efficient manner, the Company holds the Board of Directors meeting on a specified date each month, and extraordinary meetings of the Board of Directors as necessary. The Board of Directors meeting deliberates important issues related to business management, passes resolutions for such issues, and supervises the Directors' execution of their duties, etc.

2) The Group Management Committee sufficiently examines in advance any matters to be discussed and reported to the Board of Directors, so that the Company will be able to maintain the efficient and practical operation of the Board of Directors meeting.

3) In order to ensure that the Directors execute their duties in an efficient manner, the Company stipulates the "Organizational Rules," "Rules on Division of Duties," and "Rules on Duties and Authorities," appoints a person in charge of each set of rules, and formulates procedures for the enforcement of each set of rules.

4) Through the Board of Directors meeting, the Company periodically checks the progress of the Company group's business activities based on a medium-term management plan and an annual management plan.

(6) System to ensure the proper business execution of the Company group

1) System under which the Directors, etc., of subsidiaries report to the Company about matters related to the execution of their duties

The Company has established decision-making standards for business execution by subsidiaries. Any business execution that is considered important under the standards will be discussed at and reported to the Group Management Committee, and where necessary, discussed at and reported to the Board of Directors meeting. Subsidiaries are required to make reports pursuant to the "Affiliates Management Rules," for the purpose of subsidiary management.

2) Rules and other systems concerning the management of the risk of loss of subsidiaries

In order to properly address the "management risk" referred to in the "Risk Management Basic Rules," the Company has established the Group Compliance Risk Management Committee, for the purpose of promoting group-wide risk management.

3) System to ensure that the Directors, etc., of subsidiaries execute their duties in an efficient manner
Pursuant to the basic policies stipulated in the "Affiliates Management Rules," the Company has established the reporting system for the purpose of subsidiary management, and the Group Management Committee discusses important issues related to subsidiaries.

4) System to ensure that the Directors, etc., and employees of subsidiaries execute their duties in compliance with laws and regulations and the Articles of Incorporation

a. The Company ensures that subsidiaries will fully comply with the rules of conduct in accordance with the ethical standards prescribed in the Ethical Code for securing proper business execution.

b. Through internal audits periodically conducted by the Company, the Company audits the business of subsidiaries in order to ensure the proper business execution of subsidiaries.

(7) System related to certain employees to be assigned to assist with the duties of the Audit and Supervisory Committee

- 1) Where necessary, the Company appoints certain employees to be assigned to assist the Audit and Supervisory Committee.
- 2) When the Company appoints certain employees to be assigned to assist with the duties of the Audit and Supervisory Committee, matters related to the appointment, transfer, and other personnel affairs of such employees will be determined through discussion with the Audit and Supervisory Committee or with the Full-time Audit and Supervisory Committee Member.

(8) Matters concerning reports to the Audit and Supervisory Committee

- 1) The Audit and Supervisory Committee Members attend important decision-making meetings including the Board of Directors meetings or inspect minutes and other materials thereof as necessary, and receive reports on important matters from the Directors and employees of the Company group.
- 2) If there is any significant event that may cause considerable damage to the Company, such as a violation of laws and regulations and the Articles of Incorporation, the Directors and any equivalent employees will immediately report such event to the Audit and Supervisory Committee or to the Full-time Audit and Supervisory Committee Member.
- 3) Decision-making documents (*Ringi* documents) are forwarded to the Audit and Supervisory Committee Members immediately after the final decision has been made on the decision-making documents.

(9) System to ensure that any person who has made a report to the Audit and Supervisory Committee will not be treated disadvantageously on the grounds of having made such report

When any of the officers and employees of the Company group has made a report to the Audit and Supervisory Committee or to the Full-time Audit and Supervisory Committee Member, it is prohibited to treat him/her disadvantageously on the grounds of having made such report, and all the officers and employees of the Company will be fully familiarized with such prohibition.

(10) Matters related to the advance payment or reimbursement procedures for expenses incurred for the Audit and Supervisory Committee Members' execution of their duties, and other policies concerning the processing of expenses or obligations incurred for the Audit and Supervisory Committee Members' execution of their duties

- 1) The Company bears the expenses necessary for the audits conducted by the Audit and Supervisory Committee, including expenses for lawyers, certified public accounts, consultants, etc., exclusively hired by the Audit and Supervisory Committee.
- 2) In addition to the expenses described above, the Company also bears any other expenses necessary for the Audit and Supervisory Committee Members' execution of their duties.

(11) Other systems to ensure that the Audit and Supervisory Committee will conduct the audits in an effective manner

- 1) The Representative Director exchanges opinions and communicates with the Audit and Supervisory Committee, by holding periodical meetings with the Audit and Supervisory Committee to discuss various issues, including issues to be addressed by the Company, the status of improvement of the environment for the Audit and Supervisory Committee's audits, and important issues related to the audits.
- 2) The Audit and Supervisory Committee periodically receives reports from the Accounting Auditors about plans, methods and results of the accounting audits, and exchanges information with the Accounting Auditors, for the purpose of conducting audits in an efficient manner.
- 3) The Internal Audit Division provides the Audit and Supervisory Committee with internal audit results, internal audit information and other necessary information, and maintains close collaboration with the Audit and Supervisory Committee. Furthermore, the Audit and Supervisory Committee may request investigation on audit matters and other relevant issues to the Internal Audit Division as necessary.
- 4) The Company assures the Audit and Supervisory Committee Members that the Audit and Supervisory Committee Members are entitled to conclude a consultancy contract with lawyers who are dedicated to the Audit and Supervisory Committee, in addition to the corporate lawyers hired by the Company.

(12) Basic concept and system for the elimination of antisocial forces

The Company will stand firmly against antisocial forces and organizations that threaten the order and safety of civil society. In order to prevent antisocial forces and organizations from being involved in the Company's management activities and from harming the Company, the Company will stipulate, as its basic policy, in the Ethical Code that it thoroughly cuts off relations with antisocial forces and organizations. At the same time, the Company will work to eliminate relations with them by developing its organizational system, collecting information on them in cooperation with the police, and raising awareness among its directors and employees.

The following outlines the operational status of the internal control system, pursuant to the basic policies described above, during the fiscal year under review.

(1) Efforts to ensure the properness and efficiency of business execution

The Company holds the Board of Directors meeting, in principle once a month, and the Group Management Committee meeting, in principle twice a month, in order to sufficiently deliberate business plans and other important management-related issues from the perspective of properness and efficiency. Out of the 11 Directors (excluding those who are Audit and Supervisory Committee Members) of the Company, 2 Directors are Outside Directors, and all of 3 Directors who are Audit and Supervisory Committee Members of the Company are Outside Directors. The Outside Directors and Outside Audit and Supervisory Committee Members attend important meetings, including the meetings referred to above, and express their opinions, etc., where necessary and on a timely basis. In addition, the Company has established and operates the framework under which the decision-making documents (*Ringi* documents) are forwarded to the Audit and Supervisory Committee Members and other information necessary for audits is transmitted to the Audit and Supervisory Committee Members.

(2) Compliance promotion and risk management system

The Company has established the "Risk Management Basic Rules" under which the Group Compliance Risk Management Committee, chaired by the person designated by the president, deliberates on important issues concerning the promotion of compliance and risk management of the Company and the Company group, and adopts the policy resolution.

In order to promote compliance, the Company conducts educational training and awareness-raising activities using the "Ethical Code" to increase awareness and knowledge among employees not only of the Company but also of the Company group.

Taking it seriously that in June 2021 one of the employees of the Company and TOHO PHARMACEUTICAL CO., LTD., the Company's consolidated subsidiary, were convicted of violating the Antimonopoly Act in relation to an open competitive bidding for drugs ordered by the Japan Community Health care Organization, the president of the Company himself undertakes the role of chairman of the Group Compliance and Risk Management Committee, taking the initiative to strengthen compliance with laws and regulations.

Specific examples of initiatives are as follows:

- Top management ensures at a group morning meeting on TV held every month that all the employees of the Company group should comply with the Antimonopoly Act.
- As a compliance training program, the Company designates monthly themes such as compliance with laws and regulations, such as the Antimonopoly Act, the fair competition code for wholesaling, anti-bribery policies, and pharmaceutical laws and regulations, and requires all employees to attend.
- Focusing on compliance with industry-related laws and regulations, including compliance with the Antimonopoly Act, we have provided training for all the sales staff. To develop managers as instructors for in-house training, we invited a lawyer, who has expertise in the pharmaceutical wholesale industry and in-depth knowledge of industry-related laws and regulations including the Antimonopoly Act, as a lecturer so that they could learn the necessary skills for in-house instructors, such as legal knowledge, roles, missions, and attitude, and they provided non-management-level employees with more practical and effective training.
- For senior management and employees at five pharmaceutical wholesaling subsidiaries of TOHO PHARMACEUTICAL CO., LTD. provision of training on the Antimonopoly Act is also mandatory and the Company will reinforce efforts to achieve thorough compliance with laws as a whole group.

In terms of risk management, the Company regularly conducts interviews within the Company and with the Company group regarding the occurrence of risks that may affect business activities, reports the results to the Group Compliance and Risk Management Committee and the Group Management Committee, and takes appropriate countermeasures.

The Company has also developed an internal reporting system with internal and external reporting contacts with the aim of early detection and prevention of violations of laws and regulations, misconduct, etc., as well as enhancement of self-purification.

(3) Group management system

In terms of the management of the Company's group companies, the Company organizes the reporting system for the management of subsidiaries, and has established the system in which important issues are discussed with the Group Management Committee, pursuant to the "Affiliates Management Rules." The Group Audit

Office, as the Company's internal audit division, conducts internal audits of group companies, in accordance with audit plans.

(4) Efforts to ensure the effectiveness of audits

The Company's Audit and Supervisory Committee Members attend important meetings such as the Board of Directors meetings and the Group Management Committee meetings, to obtain information regarding business execution and management and information relevant to the effectiveness of the internal control system.

Furthermore, in order to ensure the effectiveness of audits, the Company has ensured close cooperation, including a system where the Audit and Supervisory Committee Members receive reporting on a periodical and occasional basis from, and exchange opinions with, the Accounting Auditor and the Group Audit Office, as well as a system where the Audit and Supervisory Committee Members periodically hold meetings and exchange opinions with the Representative Director, the head of each division and other employees.

Consolidated Statement of Changes in Shareholders' Equity

(April 1, 2021 - March 31, 2022)

(In millions of yen)

	Shareholders' equity				
	Share capital	Capital surplus	Retained earnings	Treasury stock	Total shareholders' equity
Balance as of April 1, 2021	10,649	49,378	168,872	-15,784	213,117
Cumulative effect of changes in accounting policies			-19		-19
Balance at the beginning of the current fiscal year, reflecting changes in accounting policies	10,649	49,378	168,852	-15,784	213,097
Changes of items during the consolidated fiscal year					
Dividends from surplus			-2,116		-2,116
Profit attributable to owners of parent			13,379		13,379
Purchase of treasury stock				-0	-0
Disposal of treasury stock		-4		65	61
Change in the scope of consolidation		-146	245		99
Reversal of revaluation reserve for land			-107		-107
Net changes of items other than shareholders' equity during the consolidated fiscal year					
Total changes of items during the consolidated fiscal year		-150	11,401	64	11,315
Balance as of March 31, 2022	10,649	49,228	180,254	-15,719	224,413

	Accumulated other comprehensive income			Subscription rights to shares	Non-controlling interests	Total net assets
	Valuation difference on available-for sale securities	Revaluation reserve for land	Total accumulated other comprehensive income			
Balance as of April 1, 2021	28,506	-4,380	24,125	162	—	237,405
						-19
	28,506	-4,380	24,125	162	—	237,385
Changes of items during the consolidated fiscal year						
Dividends from surplus						-2,116
Profit attributable to owners of parent						13,379
Purchase of treasury stock						-0
Disposal of treasury stock						61
Change in the scope of consolidation						99
Reversal of revaluation reserve for land						-107
Net changes of items other than shareholders' equity during the consolidated fiscal year	-7,714	107	-7,606	-13	199	-7,420
Total changes of items during the consolidated fiscal year	-7,714	107	-7,606	-13	199	3,895
Balance as of March 31, 2022	20,792	-4,273	16,518	149	199	241,281

(Note) Reported amounts are rounded down to the nearest million yen.

Notes to Consolidated Financial Statements

1. Basis for Preparation of Consolidated Financial Statements

(1) Scope of consolidation

1) Consolidated subsidiaries

- Number of consolidated subsidiaries: 22
- Names of principal consolidated subsidiaries:

TOHO PHARMACEUTICAL

Kyushu Toho

SAYWELL

Koyo

SQUARE-ONE

Toho System Service

Pharma Cluster

Pharma-Daiwa

J. Mirai Medical

Shimizu Pharmacy

Pharma Mirai

Seiko Medical Brain

VEGA PHARMA

Cure

Aobado

Kosei

KYOSOMIRAI PHARMA

Tokyo Research Center of Clinical Pharmacology

ALF

Nextit Research Institute

eKenkoshop

eHealthcare

Nextit Research Institute, eKenkoshop and eHealthcare, which were as non-consolidated subsidiaries in the previous fiscal year, have been included in the scope of consolidation from the fiscal year under review owing to their increased importance.

2) Non-consolidated subsidiaries

- Names of principal non-consolidated subsidiaries:

Okinawa Toho Co., Ltd.

- Reason for exclusion from the scope of consolidation:

The non-consolidated subsidiary is excluded from the scope of consolidation, because its business size is small, it does not have a significant impact on the total assets, net sales, consolidated net income or loss, and retained earnings, etc., and its overall impact is negligible.

(2) Application of the equity method

1) Number of affiliates to which the equity method is applied: 4

- Names of principal companies:

SAKAI MEDICINES CO., LTD.

AYM HD K.K.

AYUMI Pharmaceutical Holdings

AYUMI Pharmaceutical Corporation

Since the Company acquired the shares of AYM HD K.K., AYM HD K.K., AYUMI Pharmaceutical Holdings, and AYUMI Pharmaceutical Corporation are included in the scope of application of the equity method from the current consolidated fiscal year. As AYM HD K.K. assumes the deemed acquisition date as the end of the current consolidated fiscal year, the consolidated statements of income for the current consolidated fiscal year do not include the results of AYM HD K.K., AYUMI Pharmaceutical Holdings, and AYUMI Pharmaceutical Corporation. AYM HD K.K. merged with AYUMI Pharmaceutical Holdings on April 1, 2022, and changed its name to AYUMI Pharmaceutical Holdings.

2) Non-consolidated subsidiaries and affiliates to which the equity method is not applied:

- Names of principal non-consolidated subsidiaries:

Okinawa Toho Co., Ltd.

- Names of principal affiliates:

Wakaba

- Reason for exclusion from the scope of application of the equity method:

The non-consolidated subsidiary and affiliate to which the equity method is not applied is excluded from the scope of application of the equity method, because it does not have a significant impact on the consolidated net income or loss, and retained earnings, etc., and they are overall negligible.

(3) Fiscal year, etc. of consolidated subsidiaries

The last day of the fiscal year of consolidated subsidiaries is the same as the day of the consolidated settlement.

(4) Accounting standards

1) Standards and methods for the valuation of securities

Held-to-maturity bonds: Amortized cost method (Straight-line method)

Other securities

- Securities other than shares, etc. without market value:

The fair value method based on the market price, etc., as of the last day of the consolidated fiscal year (All valuation differences are reported as a component of net assets, with the cost of securities sold calculated according to the moving-average method.)

- Shares, etc. without market value:

The cost method using the moving-average method.

For securities with no market value, the Company compares the amount of net assets per share with the acquisition cost and considers whether or not impairment is necessary if the amount of net assets per share is less than 50% of the acquisition cost. However, if it is deemed reasonable to take the

value reflecting future excess earning power, etc. as the real value, the Company considers whether or not impairment is necessary for the real value to be applied instead of the amount of net assets.

As for investments in limited liability investment partnerships and other similar partnerships (considered as securities according to Article 2, Paragraph 2 of the Financial Instruments and Exchange Act), the net amount equivalent to equity based on the most recent available financial report of the partnership, according to the reporting date stipulated in the partnership contract, is recorded.

- 2) Valuation standards and valuation method for inventories: The cost method using the moving-average method is used for the 4 consolidated subsidiaries (TOHO PHARMACEUTICAL, Kyushu Toho, SAYWELL and Koyo) (The method of writing down the book value due to decreased profitability).

KYOSOMIRAI PHARMA CO., LTD. is stated at cost method of the first-in, first-out basis (method of write-down of book value due to decline in profitability).

The cost method using the last cost method is used for other consolidated subsidiaries (The method of writing down the book value due to decreased profitability).

- 3) Depreciation method for fixed assets

- i) Property, plant and equipment (excluding lease assets)

The fixed-rate method is applied (However, the straight-line method is applied for buildings (excluding auxiliary facilities of buildings) acquired on or after April 1, 1998 and for auxiliary facilities of buildings and structures acquired on or after April 1, 2016).

Principal useful lives are as follows:

Buildings and structures: 8-50 years

Machinery, equipment and vehicles: 4-8 years

Furniture and fixtures: 5-15 years

- ii) Intangible assets (excluding lease assets)

The straight-line method. However, the straight-line method over the internal useful life (five years) is used for computer software for internal use.

- iii) Lease assets

Lease assets pertaining to finance lease transactions, without transferring the ownership of the leased assets to the lessee.

The straight-line method with no residual value is applied and the lease term is considered to be the useful life.

- 4) Standards for reporting significant allowances and provisions

- i) Allowance for doubtful accounts

The allowance for doubtful accounts is provided to cover bad-debt losses on accounts receivable, loans, etc. In cases of ordinary receivables, the amount calculated using the loan loss ratio is provided, and in cases of specific receivables such as doubtful accounts, the recoverability is individually assessed and the estimated irrecoverable amount is provided.

- ii) Provision for bonuses

The reserve for the payment of bonuses to employees and officers who perform duties as employees is provided, based on the estimated amount of bonuses payable for the consolidated fiscal year under review.

iii) Provision for directors' bonuses

The reserve for the payment of bonuses to directors is provided, based on the estimated amount of bonuses payable for the consolidated fiscal year under review.

iv) Provision for loss on the Antimonopoly Act

To prepare for the occurrence of losses related to the Antimonopoly Act, an estimated amount is recorded as of the end of consolidated fiscal year under review.

5) Revenue and expense recording standards

The details of major performance obligations of major businesses relating to revenue arising from contracts with customers of the Company and its consolidated subsidiaries and the ordinary time of fulfillment of such performance obligations (ordinary time of recognition of revenue) are as follows.

i) Pharmaceutical Wholesaling

In Pharmaceutical Wholesaling, the Company sells prescription pharmaceuticals, reagents, test equipment, customer support systems, etc. to medical institutions, etc., and provides maintenance services related to customer support systems. In addition, equipment manufacturers, etc. are involved in some of the sales of test equipment, etc., and the Company group's performance obligation is to arrange for the equipment manufacturers, etc. to provide test equipment, etc. to customers and collect the money from the customers. For this reason, the Company has determined that the Company's group engages in transactions as an agent in such transactions. In addition, the Company group is obligated to accept returns under its sales contract for prescription pharmaceuticals, and is obligated to refund the price of the product when the product is returned from the customer.

Sales of prescription pharmaceuticals, reagents, test equipment, customer support systems, etc. are recognized as revenues at the time of delivery or acceptance of the product to the customer, since control over the product is transferred to the customer through delivery or acceptance of the product and the performance obligation is satisfied. However, these transactions are all domestic sales and are delivered to customers on the day of shipment or the following day. Therefore, revenue is recognized at the time of delivery based on the judgment that it is the normal number of days required for shipment and delivery. An obligation to perform maintenance services, etc. that is satisfied for a certain period of time is recognized as revenue on a straight-line basis according to the period in which the obligation to perform is deemed to have been satisfied because the customer receives benefits throughout the service provision period.

ii) Dispensing Pharmacy

In Dispensing Pharmacy, prescription pharmaceuticals are mainly prescribed to patients with dosing guidance, and dispensing fees are received based on the points of dispensing fees stipulated in the Health Insurance Act.

Prescriptions for prescription pharmaceuticals are recognized as revenues when the drugs are delivered to patients and dosing guidance is implemented, because the control over the drugs is transferred and the performance obligation is satisfied.

iii) Pharmaceutical Manufacturing and Sales

In Pharmaceutical Manufacturing and Sales, the Company manufactures and sells prescription pharmaceuticals, mainly generic drugs.

Prescription pharmaceuticals sales are recognized as revenue when a product is delivered to a customer because the delivery of the product transfers control over the product to the customer and fulfills performance obligations. However, since this transaction is a domestic sale and is delivered to the customer on the day of shipment or the following day, the Company judges that it is a normal number of days required for shipment and delivery, and recognizes the time of shipment as the time of delivery to determine the time of revenue recognition.

iv) Other peripheral businesses

In other peripheral businesses, the Company sells customer support systems and information processing equipment, etc., creates websites for medical institutions, and provides maintenance services related to customer support systems.

In the sales of customer support systems, information processing equipment, etc., and the creation of websites for medical institutions, revenue is recognized at the time of delivery of products to customers or acceptance of products, since control over the products is transferred to customers through delivery or acceptance of products, and performance obligations are satisfied. An obligation to perform maintenance services, etc. that is satisfied for a certain period of time is recognized as revenue on a straight-line basis according to the period in which the obligation to perform is deemed to have been satisfied because the customer receives benefits throughout the service provision period.

6) Other significant matters for preparation of consolidated financial statements

i) Accounting treatment method for retirement benefits

When calculating retirement benefit obligations and costs, eight consolidated subsidiaries (Pharma-Daiwa, J. Mirai Medical, Pharma Mirai, VEGA PHARMA, KYOSOMIRAI PHARMA, Tokyo Research Center of Clinical Pharmacology, ALF and Nextit Research Institute) are subject to the application of the simplified method, under which the hypothetical amount required to be paid for all employees upon their retirement for personal reasons as of the end of the fiscal year is considered to be the amount of retirement benefit obligations.

In line with the full transition to the defined contribution pension system, the Company and two consolidated subsidiaries (TOHO PHARMACEUTICAL and Toho System Service) have introduced an interim measure for compulsory retirees, who were employed at the time of the transition. Under the interim measure, part of the retirement benefits payable for past services rendered by the employees is paid as a retirement lump-sum payment. Accordingly, the retirement benefit obligations as of the end of March 2022 are provided to cover the payment of the retirement benefits for the employees. Because the actuarial differences are minor, they are treated as costs in each year when actuarial differences arise.

ii) Depreciation method and period of goodwill and negative goodwill

Goodwill, and negative goodwill that comes to exist by March 31, 2010, are evenly depreciated over 5 or 10 years.

2. Notes on Changes in Accounting Policies

(Application of Accounting Standards for Revenue Recognition)

Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, March 31, 2020). Applying the following (hereinafter referred to as "Accounting Standard for Revenue Recognition") at the beginning of the consolidated fiscal year under review, the Company will recognize revenues at the amount expected to be received in exchange for the promised goods or services when control of the goods or services is transferred to the customer. As a result, with respect to sales with the right to return, the Company previously recorded provision for sales return based on the amount equivalent to gross profit. However, for goods or products that are expected to be returned, in accordance with the provisions on variable consideration, the Company has changed the method to recognize the refund liability based on the amount received or received for the goods or products without recognizing the revenue at the time of sale. In addition, for some transactions related to Pharmaceutical Wholesaling, revenue was previously recognized as a total amount, but as a result of determining the role (principal or agent) in providing goods or services to customers, revenue is recognized as a net amount.

With regard to the application of the Accounting Standard for Revenue Recognition, etc., following the transitional treatment stipulated in the proviso of Section 84 of the Accounting Standard for Revenue Recognition, the cumulative effect of retroactively applying the new accounting policy prior to the beginning of the current consolidated fiscal year is added to or subtracted from retained earnings at the beginning of the current consolidated fiscal year, and the new accounting policy is applied from the balance at the beginning of the current consolidated fiscal year. However, the new accounting policy has not been applied retroactively to contracts for which the method set forth in Article 86 of the Accounting Standard for Revenue Recognition has been applied and for which the amount of almost all revenue has been recognized prior to the beginning of the current consolidated fiscal year in accordance with the previous treatment. In addition, the Company applies the method set forth in Paragraph 86 of the Accounting Standard for Revenue Recognition and in the description (1), and accounts for any contractual changes made prior to the beginning of the current consolidated fiscal year based on the contractual conditions after reflecting all contractual changes, and adds or subtracts the cumulative effect to/from retained earnings at the beginning of the current consolidated fiscal year.

As a result, retained earnings in the consolidated statements of changes in shareholders' equity at the beginning of the year decreased by 19 million yen. In addition, net sales for the current consolidated fiscal year decreased by 1,589 million yen, cost of sales decreased by 1,592 million yen, and gross profit, operating profit, ordinary profit, and income before income taxes increased by 2 million yen each.

In the consolidated balance sheets for the previous consolidated fiscal year, "notes and accounts receivable," which was presented under "current assets," is presented separately under "notes receivable-trade" and "accounts receivable-trade," and "other" which was presented under "current liabilities," is presented separately under "contractual liabilities" and "other" from the current consolidated fiscal year.

(Application of Accounting Standards for Accounting Standard for Fair Value Measurement)

Accounting Standard for Fair Value Measurement (ASBJ Statement No. 30, July 4, 2019). Applying the following (hereinafter referred to as "Accounting Standard for Fair Value Measurement") at the beginning of the consolidated fiscal year under review, in accordance with the transitional treatment set forth in Paragraph 19 of the Accounting Standard for Fair Value Measurement and Section 44-2 of the Accounting Standard for Financial Instruments (ASBJ Statement No. 10, July 4, 2019), the new accounting policies set forth in the Accounting Standard for Fair Value Measurement shall be applied in the future. There is no impact on the consolidated financial statements.

3. Notes on Accounting Estimates

(1) Valuation of stocks of non-consolidated subsidiaries without market value

1) The amount recorded in the consolidated financial statements for the consolidated fiscal year under review

Investment securities: 1,750 million yen

2) Information contributing to understand the content of accounting estimates

The Company group adopts the cost method using the moving-average method for stocks of its non-consolidated subsidiaries and affiliates without market value. When the net asset value per share is lower than 50% of the acquisition cost, it will be examined for impairment loss. In addition, if it is judged that it is reasonable to take the value reflecting future excess earning power, etc. as the real value, the Company examines the necessity of impairment accounting using the real value instead of the amount of net assets. In assessing the need for impairment, the Company has a policy not to recognize impairment losses if it determines that excess earning power, etc. has not been impaired by obtaining business plans, etc. from the

investee and taking into account the past performance, etc., or if it prepares an investment value recovery plan for the Company group and, although the real value is more than 50% below the acquisition cost, there is a feasible and reasonable investment value recovery plan and the recoverability is supported by sufficient evidence.

The major assumptions in the business plan and the adjusted investment value recovery plan that form the basis for future calculation of excess earning power are the sales growth rate and gross profit margin. In formulating the investment recovery plan, the sales growth rate and the gross profit margin will reflect the past performance and the effects of specific support measures, and targets without specific support measures will be adjusted to a reasonable and practicable level by being stressed.

The key assumptions of estimates of the sales growth rate and gross profit margin are highly uncertain. If the Company is unable to achieve its investment recovery plan due to changes in the sales growth rate and gross profit margin, it may record impairment loss of stocks of non-consolidated subsidiaries without market value.

(2) Provision for loss on the Antimonopoly Act

1) The amount recorded in the consolidated financial statements for the consolidated fiscal year under review

Gain on reversal of Provision for loss on Antimonopoly Act: 162 million yen; provision for loss on the Antimonopoly Act: 3,639 million yen

2) Information contributing to understand the content of accounting estimates

Provision for loss on Antimonopoly Act is recorded in order to prepare for the payment of penalty charges based on the contract with Japan Community Health care Organization (JCHO) for the violation of the Antimonopoly Act with respect to bidding to supply prescription pharmaceuticals to JCHO.

TOHO PHARMACEUTICAL, a consolidated subsidiary, received a cease and desist order and surcharge payment order under the Antimonopoly Act from Fair Trade Commission on March 30, 2022. The amount of penalty is estimated to be incurred in the future for transactions for 4 years prior to June 2020, based on the terms of the contract with JCHO and the opinions of the corporate counsel.

However, since these estimates are subject to uncertainties depending on the intention of the counterparties, additional recording or reversal of provision for loss related to the Antimonopoly Act could eventually be necessary due to an unpredictable change in precondition, etc.

The amount of losses expected to be incurred from this transaction has already been recorded as Provision for loss on Antimonopoly Act in the fiscal year ended March 2021. In response to these orders, a portion of Provision for loss on Antimonopoly Act was reversed at the end of the current fiscal year.

4. Notes to the Consolidated Balance Sheet

(1) Outstanding receivables arising from contracts with customers

Notes receivable-trade	2,212 million yen
Accounts receivable-trade	299,384 million yen
Others	1,424 million yen

(2) Accumulated depreciation of property, plant and equipment 59,766 million yen

(3) Assets provided as security and obligations pertaining to security

1) Assets provided as security

Fixed-term deposits	165 million yen
Buildings	1,427 million yen
Land	3,725 million yen
Investment securities	2,017 million yen
Total	7,335 million yen

2) Obligations pertaining to security

Notes payable and accounts payable	17,293 million yen
Long-term borrowings (including those to be reimbursed within 1 year)	1,743 million yen
Total	19,037 million yen

(4) Guarantee obligations

Bank guarantee obligations	396 million yen
----------------------------	-----------------

(5) Land revaluation

Pursuant to the "Act on Revaluation of Land" (Act No. 34 of March 31, 1998) and the "Act for Partial Revision of the Act on Revaluation of Land" (Act No. 19 of March 31, 2001), land for business use has been revaluated, and the amount obtained by deducting the "deferred tax liabilities pertaining to revaluation" from the revaluation differences is reported as the "revaluation reserve for land" in the net assets section.

Revaluation method

The calculation is based on the land tax ledger referred to in Article 2, Item (3) of the "Order for Enforcement of the Act on Revaluation of Land" (Cabinet Order No. 119 of March 31, 1998).

Date of revaluation March 31, 2002

The difference between the fair value of the revaluated land as of the end of the consolidated fiscal year under review and the book value after the revaluation of the revaluated land

438 million yen

(6) Contingent liability

On November 9, 2021, Kyushu Toho Co., Ltd., the Company's consolidated subsidiary, received an on-site inspection by the Fair Trade Commission on suspicion of violation of the Antimonopoly Act with respect to the bidding for prescription pharmaceuticals in the Kyushu region ordered by the National Hospital Organization (NHO). The investigation is ongoing.

These results may have an impact on the Company group's consolidated financial results in the future, but it is currently difficult to reasonably estimate the impact.

5. Notes to Consolidated Profit and Loss Statement

The amount of revenue generated from contracts with customers in net sales 1,265,981 million yen

6. Notes to the Consolidated Statement of Changes in Shareholders' Equity

(1) Types and total number of shares issued, and types and number of treasury shares

Type of shares	Number of shares at the beginning of the fiscal year under review	Number of increased shares during the fiscal year under review	Number of decreased shares during the fiscal year under review	Number of shares at the end of the fiscal year under review
Shares issued				
Common stocks	78,270 thousand shares	—	—	78,270 thousand shares
Total	78,270 thousand shares	—	—	78,270 thousand shares
Treasury shares				
Common stocks (Notes)	7,759 thousand shares	1 thousand shares	32 thousand shares	7,729 thousand shares
Total	7,759 thousand shares	1 thousand shares	32 thousand shares	7,729 thousand shares

(Notes) 1. The treasury shares of common stocks increased by 1 thousand shares, consisting of an increase of 0 thousand shares due to the stock acquisition for no consideration associated with restricted stock compensation and an increase of 1 thousand shares due to purchase of common stocks representing less than one unit.

2. The decrease in treasury stock of 32 thousand shares of common stock was a decrease of 25 thousand shares due to the disposal as restricted stock compensation and a decrease of 7 thousand shares due to the exercise of stock options.

(2) Subscription rights to shares, etc.

Company name	Breakdown	Type of target shares	Number of target shares (Thousand shares)				Balance as of the end of the consolidated fiscal year under review (Million yen)
			Beginning of the consolidated fiscal year under review	Increase	Decrease	End of the consolidated fiscal year under review	
Filing company	Euro-yen convertible corporate bonds due 2023 with subscription rights to shares (Notes 1 and 2)	Common stocks	6,000	—	—	6,000	—
	Share acquisition	Common stocks	78	—	7	71	149

	rights as stock options (Notes 3)						
Total		6,079	—	7	6,072	149	

- (Notes)
1. The above number of the target shares of share acquisition rights is the number of shares calculated based on the presumption that the subscription rights to shares options have been exercised.
 2. For the convertible bonds with share subscription rights, the all-inclusive method is used.
 3. The decrease of 7 thousand shares in the number of target shares of share acquisition rights as stock options is attributable to exercise of the rights.

(3) Dividends from surplus

1) Dividends from surplus, paid during the consolidated fiscal year under review

Resolution	Types of shares	Total amount of dividends	Dividends per share	Record date	Effective date
Meeting of the Board of Directors held on May 14, 2021	Common stocks	1,057 million yen	15 yen	March 31, 2021	June 9, 2021
Meeting of the Board of Directors held on November 12, 2021	Common stocks	1,058 million yen	15 yen	September 30, 2021	December 10, 2021

2) Dividends for which the record date falls during the consolidated fiscal year under review but for which the effective date is in the next consolidated fiscal year

Resolution	Types of shares	Total amount of dividends	Dividends per share	Record date	Effective date
Meeting of the Board of Directors held on May 13, 2022	Common stocks	1,058 million yen	15 yen	March 31, 2022	June 9, 2022

(Note) It is planned that retained earnings will be the divided resource.

7. Notes to Financial Instruments

1. Status of financial instruments

(1) Policies toward financial instruments

According to the Company group's policy, only products with a high level of safety, such as fixed-term deposits, are used for fund management, and borrowings from banks and other financial institutions and bond issuance are used as its primary means of fund procurement. The Company group enters into derivative transactions for the purpose of hedging the risk of interest rate fluctuations, and not for speculative purposes.

(2) Contents and risks of financial instruments and risk management system

Notes and accounts receivable, which are trade receivables, are exposed to customer credit risk. With respect to such risk, the Company group maintains the system in which the schedule and balance are managed for each trade partner and the credit status of major trade partners is monitored where necessary, pursuant to the Company group's accounts receivable management rules.

Regarding the shares considered as investment securities by the Company group, the shares are mainly those of the companies with which the Company group has a business relationship. Although the shares are exposed

to the risk of market price fluctuations, the finance division periodically checks the market prices in order to control the risk.

The notes and accounts payable, which are trade payables, will become due within one year.

Regarding borrowings, the Company group uses a short-term borrowing method mainly for the purpose of procuring funds for business transactions, or as a short-term bridge loan to be borrowed until investment funds are procured by means of long-term borrowings; the Company group uses long-term borrowings and corporate bonds mainly for the purpose of making capital investments. The Company group uses long-term borrowings mainly at fixed interest rates to mitigate the risk of interest rate fluctuations.

The finance division is responsible for the execution and management of derivative transactions, and when executing a derivative transaction, approval is obtained in advance pursuant to internal rules for the execution of derivative transactions, as well as hedged borrowing. The Company group enters into derivative transactions only with financial institutions with a high credit rating, in order to reduce the credit risk. The Company group did not engage in derivative transactions in the consolidated fiscal year under review.

Trade payables and borrowings are exposed to liquidity risk. The Company group controls the risk by ensuring that each company prepares monthly cash flow plans, and by taking other measures.

(3) Supplementary information on the fair value, etc., of financial instruments

The fair value of financial instruments is based on market prices or reasonable calculations in the absence of market prices. Since various assumptions and factors are reflected in estimating said value, different assumptions and factors could result in a different value.

2. Fair value, etc., of financial instruments

The amounts reported in the consolidated balance sheet, fair values, and differences between them as of March 31, 2022 are as follows. "Cash and deposits," "Notes receivable-trade," "Accounts receivable-trade," "Accounts receivable-purchases discount," and "Notes and accounts payable-trade" are omitted because they are cash and are settled in a short period of time, and their fair values approximate their book values.

(Unit: Million yen)

	Amount reported in the consolidated balance sheet	Fair value	Difference
(1) Securities and investment securities Other securities	48,430	48,430	—
(2) Bonds payable	20,023	19,830	-193
(3) Long-term borrowings	18,894	18,866	-27

(Note 1) Matters concerning securities

(1) Securities and investment securities

The notes to the securities for each holding purpose are as follows.

1) Other securities

(Unit: Million yen)

Category	Type	Acquisition cost	Amount reported in the consolidated balance sheet	Difference
Item for which the amount reported in the consolidated balance sheet exceeds the acquisition cost	Shares	17,994	47,640	29,645
	Government bonds, municipal bonds, etc.	—	—	—
	Corporate bonds	—	—	—
	Others	13	25	12
	Subtotal	18,007	47,665	29,657
Item for which the amount reported in the consolidated balance sheet is no more than the acquisition cost	Shares	843	764	-78
	Government bonds, municipal bonds, etc.	—	—	—
	Corporate bonds	—	—	—
	Others	—	—	—
	Subtotal	843	764	-78
Total		18,850	48,430	29,579

- (Notes) 1. The acquisition cost for the current consolidated fiscal year is the amount after deducting the impairment loss of 324 million yen.
2. If the fair value as of the end of the consolidated fiscal year decreases by approximately 50% or more of the acquisition cost, an impairment loss is reported. If the fair value decreases by approximately 30-50% of the acquisition cost, the average of the fair values at the end of each month during the past one year is calculated, and if the average fair value decreases by 30% or more of the acquisition cost, an impairment loss is reported.

2) Other securities sold during the consolidated fiscal year (From April 1, 2021 to March 31, 2022)

(Unit: Million yen)

Category	Sales value	Total profit on sales	Total loss on sales
Shares	5,198	2,720	7
Bonds	—	—	—
Others	—	—	—
Total	5,198	2,720	7

(Note 2) Shares, etc. without market value are not included in "(1) Securities and investment securities."

The amounts recorded in the consolidated balance sheets of the financial instruments are as follows.

(Unit: Million yen)

Category	Amount
Unlisted stocks, etc.	30,312

(Note 3) The reimbursement schedule of monetary claims and securities with a maturity date, after the consolidated settlement date

(Unit: Million yen)

Category	Within 1 year	More than 1 year and within 5 years	More than 5 years and within 10 years	More than 10 years
Deposits	93,845	—	—	—
Notes receivable-trade	2,212	—	—	—
Accounts receivable-trade	299,389	—	—	—
Purchase rebates receivable	12,733	—	—	—
Securities and investment securities				
Held-to-maturity bonds	—	10	—	—
Other securities	78	1	—	—

(Note 4) The reimbursement schedule of corporate bonds, long-term borrowings, lease obligations and other interest-bearing debts, after the consolidated settlement date

(Unit: Million yen)

Category	Within 1 year	More than 1 year and within 5 years	More than 5 years and within 10 years	More than 10 years
Corporate bonds	—	20,000	—	—
Long-term borrowings	6,298	11,168	1,021	406

3. Matters concerning the breakdown, etc. of fair value of financial instruments by appropriate category

The fair values of financial instruments are classified into the following three levels according to the observability and significance of the inputs used to calculate the fair values.

Level 1 Fair Value: Market value of the same asset or liability, as determined by the unadjusted market value of the same asset or liability in an active market

Level 2 Fair Value: Calculated using directly or indirectly observable inputs other than Level 1 inputs
Fair value

Level 3 Fair Value: Calculated using inputs for which no significant observations can be made

If multiple inputs that have a significant impact on the calculation of fair value are used, the fair value is classified to the level with the lowest priority in the calculation of market value among the levels to which the inputs belong.

(1) Financial instruments reported on the consolidated balance sheet at fair value

(Unit: Million yen)

Category	Fair value			
	Level 1	Level 2	Level 3	Total
Securities and investment securities				
Other securities	48,430	—	—	48,430

(2) Financial instruments other than financial instruments reported on the consolidated balance sheet at fair value

(Unit: Million yen)

Category	Fair value			
	Level 1	Level 2	Level 3	Total
Corporate bonds	—	19,830	—	19,830
Long-term borrowings	—	18,866	—	18,866

(Note) Explanation of valuation techniques and inputs used to calculate fair value

Securities and investment securities

Listed shares are valued at quoted prices. As listed stocks are traded in active markets, their fair values are classified as Level 1 fair values.

Corporate bond

Corporate bonds issued by the Company are valued at quoted prices. Corporate bonds issued by the Company are classified into Level 2 fair values because the frequency of transactions in the market is low and they are not recognized as quoted prices in active markets.

Long-term borrowings

The fair value of long-term borrowings is calculated using the discounted present value method based on the total amount of principal and interest, and the interest rate that takes into account the remaining term of the debt and credit risk, and is classified into the level 2 fair value.

8. Notes to Rental Real Property

Notes are omitted because the total amount of rental real property has little significance.

9. Notes to Revenue Recognition

(1) Breakdown of revenue arising from contracts with customers

(Unit: Million yen)

	Reportable segments				Total
	Pharmaceutical Wholesaling	Dispensing Pharmacy	Pharmaceutical Manufacturing and Sales	Other Peripheral Businesses	
Prescription pharmaceuticals	1,017,126	70,738	1,851	—	1,089,716
Reagents	73,988	—	—	—	73,988
Other	76,858	21,047	48	4,321	102,276
Revenue from customer contracts	1,167,973	91,786	1,899	4,321	1,265,981
Other revenue	182	—	—	7	189
Sales to external customers	1,168,155	91,786	1,899	4,329	1,266,171

(2) Information that forms the basis for understanding revenue

1) Pharmaceutical Wholesaling

In Pharmaceutical Wholesaling, the Company sells prescription pharmaceuticals, reagents, test equipment, customer support systems, etc. to medical institutions, etc., and provides maintenance services related to customer support systems.

Sales of prescription pharmaceuticals, reagents, test equipment, customer support systems, etc. are recognized as revenues at the time of delivery or acceptance of the product to the customer, since control over the product is transferred to the customer through delivery or acceptance of the product and the performance obligation is satisfied. However, these transactions are all domestic sales and are delivered to customers on the day of shipment or the following day. Therefore, revenue is recognized at the time of delivery based on the judgment that it is the normal number of days required for shipment and delivery. An obligation to perform maintenance services, etc. that is satisfied for a certain period of time is recognized as revenue on a straight-line basis according to the period in which the obligation to perform is deemed to have been satisfied because the customer receives benefits throughout the service provision period. Advances may be received for some of the sales of maintenance services, etc., but the usual due date for payment is 60 to 90 days from the time of delivery or acceptance of the product, and the transaction price does not include any significant financial element.

In the sale of prescription pharmaceuticals, there is a practice in which the transaction price is determined through price negotiation after delivery, and as a result of price negotiation, the transaction price may change due to a discount, and this is recognized as variable compensation. For this reason, the transaction price is estimated based on the price that is most likely to be reached through price negotiation, taking into consideration the past sales performance by customer and product. The amount of variable consideration shall be included in the transaction price only to the extent that there is a high possibility that there will be no significant reduction in revenue recorded by the time when the uncertainty concerning the variable consideration is resolved ex post facto. At the end of the term, the transaction price tends to be almost decided, although the settlement will be in the next term.

Under the terms of the agreement of prescription pharmaceuticals, the Company group is obligated to accept returns, and if the customer returns the product, it is obligated to refund the price of the product. For returns, the Company calculates the expected refund amount that may occur in light of the actual returns, etc., and calculates the transaction price using the method of deducting it from revenue. As a result, the Company recognizes liability for returns and recognizes revenue only to the extent that there is a high probability that no material returns will occur.

In part of the sale of test equipment, etc., equipment manufacturers are involved in the transaction, and the Company group's performance obligation is to arrange for the equipment manufacturers, etc. to provide test equipment, etc. to customers and collect the money from the customers. For this reason, the Company has determined that the Company's group engages in transactions as an agent in such transactions. As a result, for a portion of sales of test equipment, etc., the transaction price is calculated based on the net amount obtained by deducting the amount to be paid to the equipment manufacturer, etc. from the amount of consideration received from customers.

Sales of test equipment and customer support systems and the provision of maintenance services related to customer support systems are included in "Other" in the breakdown of earnings.

2) Dispensing Pharmacy

In Dispensing Pharmacy, prescription pharmaceuticals are mainly prescribed to patients with dosing guidance and dispensing fees are received based on the points of dispensing fees stipulated in the Health Insurance Act.

Prescriptions for prescription pharmaceuticals are recognized as revenues when the drugs are delivered to patients and dosing guidance is implemented, because the control over the drugs is transferred and the compliance obligation is satisfied.

The payment of prescription pharmaceuticals and dispensing fees at health insurance pharmacies is mainly received 30% from patients at the time of prescription, and 70% from the Federation of National Health Insurance Associations or the Social Insurance Medical Fee Payment Fund approximately two months later. Therefore, none of the payments are made for a period longer than one year, and the transaction price does not include any significant financial element.

Dispensing fees are included in "Other" in the breakdown of earnings.

3) Pharmaceutical Manufacturing and Sales

In Pharmaceutical Manufacturing and Sales, the Company manufactures and sells prescription pharmaceuticals, mainly generic drugs.

Prescription pharmaceuticals sales are recognized as revenue when a product is delivered to a customer because the delivery of the product transfers control over the product to the customer and fulfills performance obligations. However, since this transaction is a domestic sale and is delivered to the customer on the day of shipment or the following day, the Company judges that it is a normal number of days required for shipment and delivery, and recognizes the time of shipment as the time of delivery to determine the time of revenue recognition.

The receivables corresponding to these revenues are normally due for payment of approximately 60 days from the date of delivery of the products, none of the payments are made for a period longer than one year, and the transaction price does not include a significant financial element.

4) Other peripheral businesses

In other peripheral businesses, the Company sells customer support systems and information processing equipment, etc., creates websites for medical institutions, and provides maintenance services related to customer support systems.

In the sales of customer support systems, information processing equipment, etc., and the creation of websites for medical institutions, revenue is recognized at the time of delivery of products to customers or acceptance of products, since control over the products is transferred to customers through delivery or acceptance of products, and performance obligations are satisfied. An obligation to perform maintenance services, etc. that is satisfied for a certain period of time is recognized as revenue on a straight-line basis according to the period in which the obligation to perform is deemed to have been satisfied because the customer receives benefits throughout the service provision period.

Advances may be received for some of the sales of maintenance services, etc., but the usual due date for payment is 60 to 90 days from the time of delivery or acceptance of the product, and the transaction price does not include any significant financial element.

Sales of customer support systems, information processing equipment, etc., creation of medical institution websites, provision of maintenance services related to customer support systems, etc. are included in "Other" in the breakdown of earnings.

(3) Information for understanding the amount of revenue for the relevant consolidated fiscal year and the following consolidated fiscal year and thereafter

1) Balance of contractual liabilities, etc.

(Unit: Million yen)

Claims arising from contracts with customers (beginning balance)	286,339
Claims arising from contracts with customers (year-end balance)	303,021
Contract Liabilities (beginning balance)	197
Contract liabilities (year-end balance)	206

Contractual liabilities mainly relate to advances received from customers for unexpired periods in relation to contracts with customers who are provided maintenance services, etc. for a certain period of time, and are reversed in accordance with recognition of income.

Of the amount of revenue recognized in the current consolidated fiscal year, the amount included in the balance of contractual liabilities at the beginning of the period was 164 million yen.

There are no significant changes in the balance of contractual liabilities.

The amount of revenue (mainly changes in transaction prices) recognized in the current consolidated fiscal year is immaterial due to performance obligations satisfied (or partially satisfied) in the past period.

2) Transaction price allocated to remaining performance obligations

The transaction price allocated to the Company group's remaining performance obligation is omitted because the amount is immaterial.

10. Notes to Per Share Information

(1) Net assets per share: 3,415.50 yen

(2) Net income per share: 189.70 yen

11. Notes to Significant Subsequent Events

Not applicable.

Statement of Changes in Shareholders' Equity

(April 1, 2021 - March 31, 2022)

(In millions of yen)

	Shareholders' Equity								
	Share capital	Capital surplus			Legal retained earnings	Retained earnings			Total retained earnings
		Legal capital surplus	Other capital surplus	Total capital surplus		Reserve for reduction entry of land	General reserve	Retained earnings brought forward	
Balance as of April 1, 2021	10,649	46,177	3,937	50,114	664	1,513	6,336	78,113	86,627
Changes of items during the fiscal year									
Dividends from surplus								-2,116	-2,116
Net income								4,014	4,014
Reversal of revaluation reserve for land								-107	-107
Reversal of reserve for reduction entry of land						-109		109	—
Purchase of treasury stock									
Disposal of treasury stock			-4	-4					
Net changes of items other than shareholders' equity during the fiscal year									
Total changes of items during the fiscal year			-4	-4		-109		1,900	1,791
Balance as of March 31, 2022	10,649	46,177	3,933	50,110	664	1,404	6,336	80,013	88,418

	Shareholders' Equity		Valuation and translation adjustments			Subscription rights to shares	Total net assets
	Treasury stock	Total shareholders' equity	Valuation difference on available-for-sale securities	Revaluation reserve for land	Total valuation and translation adjustments		
Balance as of April 1, 2021	-15,823	131,568	33,244	-4,357	28,886	162	160,617
Changes of items during the fiscal year							
Dividends from surplus		-2,116					-2,116
Net income		4,014					4,014
Reversal of revaluation reserve for land		-107					-107
Reversal of reserve for reduction entry of land		—					—
Purchase of treasury stock	-0	-0					-0
Disposal of treasury stock	65	61					61
Net changes of items other than shareholders' equity during the fiscal year			-7,776	107	-7,668	-13	-7,682
Total changes of items during the fiscal year	64	1,851	-7,776	107	-7,668	-13	-5,830
Balance as of March 31, 2022	-15,759	133,420	25,468	-4,250	21,217	149	154,787

(Note) Reported amounts are rounded down to the nearest million yen.

Notes to Non-consolidated Financial Statements

1. Notes to Significant Accounting Policies

(1) Standards and methods for the valuation of securities

Shares of subsidiaries and affiliates: The cost method using the moving-average method.

For shares of subsidiaries and affiliates with no market value, the Company compares the amount of net assets per share with the acquisition cost and considers whether or not impairment is necessary if the amount of net assets per share is less than 50% of the acquisition cost. However, if it is deemed reasonable to take the value reflecting future excess earning power, etc. as the real value, the Company considers whether or not impairment is necessary for the real value to be applied instead of the amount of net assets.

Other securities

- Securities other than shares, etc. without market value:

The fair value method based on the market price, etc., as of the last day of the fiscal year (All valuation differences are reported as a component of net assets, with the cost of securities sold calculated according to the moving-average method.)

- Shares, etc. without market value:

The cost method using the moving-average method.

For securities with no market value, the Company compares the amount of net assets per share with the acquisition cost and considers whether or not impairment is necessary if the amount of net assets per share is less than 50% of the acquisition cost. However, if it is deemed reasonable to take the value reflecting future excess earning power, etc. as the real value, the Company considers whether or not impairment is necessary for the real value to be applied instead of the amount of net assets.

For investments in an investment limited partnership or other similar partnerships (Securities as defined in Article 2, paragraph 2 of the Securities Exchange Law), the Company books the net value of proportional holdings based on the most recent available financial report of the association, according to the financial settlement date stipulated in the association contract.

(2) Depreciation method for fixed assets

1) Property, plant and equipment (excluding lease assets)

The fixed-rate method is applied (However, the straight-line method is applied for buildings (excluding auxiliary facilities of buildings) acquired on or after April 1, 1998 and for auxiliary facilities of buildings and structures acquired on or after April 1, 2016).

Principal useful lives are as follows:

Buildings and structures:	8-50 years
Furniture and fixtures:	5-15 years

2) Intangible assets

The straight-line method. However, the straight-line method over the internal useful life (five years) is used for computer software for internal use.

3) Lease assets

Lease assets pertaining to finance lease transactions, without transferring the ownership of the leased assets to the lessee.

The straight-line method with no residual value is applied and the lease term is considered to be the useful life.

4) Long-term prepaid expenses

Evenly depreciated.

(3) Standards for reporting significant allowances and provisions

1) Allowance for doubtful accounts

Allowance for doubtful accounts is provided to cover bad-debt losses on accounts receivable, loans, etc. In cases of ordinary receivables, the amount calculated using the loan loss ratio is provided, and in cases of specific receivables such as doubtful accounts, the recoverability is individually assessed and the estimated irrecoverable amount is provided.

2) Provision for bonuses

The reserve for the payment of bonuses to employees and officers who perform duties as employees is provided, based on the estimated amount of bonuses payable for the fiscal year under review.

3) Provision for directors' bonuses

The reserve for the payment of bonuses to directors is provided, based on the estimated amount of bonuses payable for the fiscal year under review.

4) Provision for retirement benefits

In line with the full transition to the defined contribution pension system in April 2005, the Company has introduced an interim measure for compulsory retirees, who were employed at the time of the transition. Under the interim measure, part of the retirement benefits payable for past services rendered by the employees is paid as a retirement lump-sum payment. Accordingly, the retirement benefit obligations as of the end of March 2022 are provided to cover the payment of the retirement benefits for the employees. Because the actuarial differences are minor, they are treated as costs in each year when actuarial differences arise.

(4) Revenue and expense recording standards

The Company provides consulting and other services to Group companies.

As the Group companies receive benefits from the performance obligations of consulting services, etc. over a certain period of time, the Company considers that the performance obligations have been satisfied during the period of service provision and recognizes revenue at a fixed amount according to the period.

2. Notes on Changes in Accounting Policies

(Application of Accounting Standards for Revenue Recognition)

Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, March 31, 2020). Applying the following (hereinafter referred to as "Accounting Standard for Revenue Recognition") at the beginning of the current fiscal year, revenues are recognized at the amount expected to be received in exchange for the promised goods or services when control of the goods or services is transferred to the customer. There is no impact on the non-consolidated financial statements.

(Application of Accounting Standards for Accounting Standard for Fair Value Measurement)
Accounting Standard for Fair Value Measurement (ASBJ Statement No. 30, July 4, 2019). Applying the following (hereinafter referred to as "Accounting Standard for Fair Value Measurement") at the beginning of the current fiscal year, in accordance with the transitional treatment prescribed in Paragraph 19 of the Accounting Standard for Fair Value Measurement and Section 44-2 of the Accounting Standard for Financial Instruments (ASBJ Statement No. 10, July 4, 2019), the new accounting policies set forth in the Accounting Standard for Fair Value Measurement shall be applied in the future. There is no impact on the non-consolidated financial statements.

3. Notes on Accounting Estimates

Valuation of stocks of non-consolidated subsidiaries without market value

1) The amount recorded in the financial statements for the fiscal year under review

Investment securities: 1,755 million yen

2) Information contributing to understanding the content of accounting estimates

This is the same as stated in Notes to Consolidated Statements, "3. Notes on Accounting Estimates (1)

Valuation of stocks of non-consolidated subsidiaries without market value."

Amount of business transactions

Business revenue

7,021 million yen

Amount of transactions other than business transactions

562 million yen

6. Notes to the Non-consolidated Statement of Changes in Shareholders' Equity

Number of treasury shares

Type of shares	Number of shares at the beginning of the fiscal year under review	Number of increased shares during the fiscal year under review	Number of decreased shares during the fiscal year under review	Number of shares at the end of the fiscal year under review
Common stocks (Notes)	7,748 thousand shares	1 thousand shares	32 thousand shares	7,717 thousand shares

(Notes) 1. The treasury shares of common stocks increased by 1 thousand shares, consisting of an increase of 1 thousand shares due to the stock acquisition for no consideration associated with restricted stock compensation and an increase of 0 thousand shares due to purchase of common stocks representing less than one unit.

2. The decrease in treasury stock of 32 thousand shares of common stock was a decrease of 25 thousand shares due to the disposal as restricted stock compensation and a decrease of 7 thousand shares due to the exercise of stock options.

7. Notes to Deferred Tax Accounting

Breakdown of deferred tax assets and deferred tax liabilities by major cause

(Millions of yen)

Deferred tax assets	
Accrued enterprise tax	82
Provision for bonuses	23
Allowance for doubtful accounts	692
Investment securities	961
Stocks of subsidiaries and affiliates	1,482
Other noncurrent liabilities	30
Impairment loss	100
Asset retirement obligations	590
Stock options	30
Restricted stock compensation	21
Others	33
Subtotal of deferred tax assets	4,049
Valuation reserve	-4,049
Total of deferred tax assets	—
Deferred tax liabilities	
Reserve for reduction entry of land	-619
Valuation differences on available-for-sale of securities	-11,343
Valuation differences of securities resulting from merger of subsidiaries	-429
Asset retirement obligations	-512
Investment securities returned from retirement benefit trust	-147
Others	-5
Total of deferred tax liabilities	-13,058
Net amount of deferred tax liabilities	-13,058

8. Notes concerning Related Party Transactions

Subsidiaries and affiliates, etc.

Attribute	Company name, etc.	Ownership ratio of voting rights, etc. (%)	Relationship with related party	Transaction content	Transaction amount (million yen)	Item	Balance as of the end of the fiscal year (million yen)
Subsidiary	TOHO PHARMACEUTICAL	Ownership Direct 100.0 %	Conclusion of business management contract Financial support Leasing of real estate properties Interlocking officers	Lending of funds	-2,724	Loans (CMS loans)	15,783
				Interest income (Notes 1)	143		
				Consulting fee income (Notes 2)	1,162		
				Real estate lease revenue (Notes 3)	3,714		
				Dividend income (Notes 4)	1,469		
				Debt guarantees (Notes 5)	9,830		
Subsidiary	Kyushu Toho	Ownership Direct 100.0 %	Financial support Interlocking officers	Deposits of funds	1,759	Deposits (CMS deposits)	7,134
				Interest due (Notes 1)	44		
Subsidiary	SAYWELL	Ownership Direct 100.0 %	Financial support	Deposits of funds	1,984	Deposits (CMS deposits)	20,288
				Interest due (Notes 1)	117		
Subsidiary	SQUARE-ONE	Ownership Direct 100.0 %	Financial support	Debt guarantees (Notes 6)	3,790	—	—
Subsidiary	Pharma Mirai	Ownership Direct 100.0 %	Financial support	Deposits of funds	1,506	Deposits (CMS deposits)	15,845
				Interest due (Notes 1)	81		

(Notes) Terms of transactions and the policy for determining the terms of transactions

1. Interest rates are determined through discussion pursuant to the Company's rules, taking into consideration market interest rates, etc. A transaction amount represents a net increase or net decrease during the fiscal year.
2. The amount of consulting fee income is determined based on the costs associated with business advisory.

3. The amount of the real estate lease revenue is determined through discussion based on current conditions of transactions in the neighboring areas.
4. The amount of the dividend income is determined based on prescribed dividend standards.
5. Debt guarantees were provided for accounts payable.
6. Debt guarantees were provided for borrowings from banks.

9. Notes to Revenue Recognition

The Company provides consulting and other services to Group companies.

As the Group companies receive benefits from the performance obligations of consulting services, etc. over a certain period of time, the Company considers that the performance obligations have been satisfied during the period of service provision and recognizes revenue at a fixed amount according to the period.

The deadline for payment of consulting fees is the last day of the month in which consulting services are provided, and the Company receives monthly payments from Group companies. None of the payments are made for a period longer than one year, and the transaction price does not include significant financial factors.

10. Notes to Per Share Information

(1) Net assets per share	2,191.82yen
(2) Net income per share	56.91 yen

11. Notes to Significant Subsequent Events

Not applicable.